Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00011934 · ClinicalTrials.gov registry record · Phase 2
Bone Marrow Transplantation Plus Biological Therapy in Treating Patients With Chronic Myeloid Leukemia
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00011934 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
The verdict
NCT00011934, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Biological therapy may increase the number of immune cells found in bone marrow and may help a person's immune system recover from the side effects of the chemotherapy used in treating chronic myeloid leukemia. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy. PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation, chemotherapy, and biological therapy in treating patients who have chronic myeloid leukemia.
Interventions
- BIOLOGICAL recombinant interferon alfa
- BIOLOGICAL sargramostim
- PROCEDURE autologous bone marrow transplantation
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-05 |
| Est. Completion | 2002-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00011934
The ClinicalTrials.gov registry entry for NCT00011934 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which recombinant interferon alfa is the first listed.
NCT00011934 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00011934 about?
NCT00011934 is a clinical study titled "Bone Marrow Transplantation Plus Biological Therapy in Treating Patients With Chronic Myeloid Leukemia". RATIONALE: Biological therapy may increase the number of immune cells found in bone marrow and may help a person's immune system recover from the side effects of the chemotherapy used in treating chronic myeloid leukemia. Bone marrow transplantation may be able to replace immune cells that were dest...
What is the current status of trial NCT00011934?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-05. Estimated completion is 2002-08.
What interventions are being tested in trial NCT00011934?
The interventions under investigation include: recombinant interferon alfa (BIOLOGICAL), sargramostim (BIOLOGICAL), autologous bone marrow transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00011934?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.